Galderma Q1 Sales Surge 25.5% as US Demand Drives Growth
Swiss skincare company Galderma reported a strong start to the year, with first-quarter sales rising 25.5% in constant-currency terms to $1.47 billion. The Zug-based firm was buoyed by robust demand in the United States, where sales jumped 41.5% year-on-year between January and March. Popular brands such as Cetaphil and Restylane contributed significantly to the growth, supported by expanding consumer interest in dermatological skincare.
The company stated that its positive performance has strengthened confidence in meeting its annual guidance despite a volatile global environment. Shares of Galderma rose over 6% following the announcement. CEO Flemming Ornskov highlighted strong uptake of its injectable dermatitis treatment Nemluvio and noted increasing traction on e-commerce platforms like Amazon, where demand for skincare products remains particularly high in the US market.
Galderma also signalled that potential exposure to US tariffs remains manageable, with no material impact expected on its 2026 financial outlook. The company is closely monitoring developments, including possible refund scenarios tied to rulings by the US Supreme Court. Additionally, Ornskov said the firm has so far mitigated disruptions linked to geopolitical tensions in the Middle East, citing a diversified supply chain and stable supply costs.
Pic Courtesy: google/ images are subject to copyright
